ImmunityBio Faces Investor Lawsuits Following a $2 Billion Drop in Market Value
San Diego, Wednesday, 29 April 2026.
ImmunityBio faces mounting lawsuits after alleged misleading claims about its cancer drug triggered an FDA warning, erasing $2 billion in market value and severely impacting shareholders.
A Wave of Legal Scrutiny
On April 29, 2026, the complex litigation law firm Lowey Dannenberg P.C. announced an investigation into ImmunityBio Inc. (NASDAQ: IBRX) for potential violations of federal securities laws [1]. The inquiry centers on a complaint originally filed on March 26, 2026, which alleges that the company and one of its officers, Patrick Soon-Shiong, materially overstated the capabilities of its lead biologic product, Anktiva [1][2]. According to the complaint, these alleged misrepresentations led to statements about the company’s business operations and prospects that were materially false, misleading, or lacked a reasonable basis [1]. Lowey Dannenberg is specifically targeting investors who suffered financial losses exceeding $100,000 in ImmunityBio securities to participate in the investigation [1].
The Catalyst: Clinical Results and FDA Warnings
The roots of this legal turbulence trace back to the beginning of the class period in early 2026. On January 23, 2026, ImmunityBio issued a press release detailing updated Phase 2 results from its QUILT 3.078 trial, which evaluated a chemotherapy-free combination immunotherapy in patients with recurrent or progressive glioblastoma [2]. The company reported that the primary endpoint of “median overall survival” had “not yet been reached” [2]. The market reacted negatively to this update; ImmunityBio’s stock price dropped by $0.89, representing a 12.13% decline, to close at $6.45 per share on that day [2].
Navigating Financials Amidst Headwinds
Despite the severe legal and regulatory headwinds, ImmunityBio has maintained a notable financial and operational baseline. In early April 2026, the company reported its first-quarter net product revenue at $44 million, representing an approximate 2.7-fold year-over-year increase [4]. Furthermore, the biotechnology firm disclosed holding $381 million in cash and marketable securities, bolstered by a $100 million financing arrangement filed on March 31, 2026 [4]. Because this financing included $75 million in non-dilutive funds, the remaining 25 million constituted dilutive financing [4].